Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2010

01-06-2010 | REVIEW

Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience

Authors: Derek G. Power, Manish A. Shah, Timothy R . Asmis, Joaquin J . Garcia, Nancy E. Kemeny

Published in: Investigational New Drugs | Issue 3/2010

Login to get access

Summary

There are two highly selective antibodies to the epidermal growth factor receptor (EGFR) now available for use in metastatic colorectal cancer (mCRC). In KRAS wild type patients, cetuximab (Cmab)-an IgG1 chimeric molecule—has activity alone and in combination with chemotherapy for the first, second and third-line settings. Panitumumab (Pmab)-a fully humanized IgG2 molecule-has activity as a single agent in chemorefractory mCRC and shows promising activity in combination with chemotherapy. It remains unclear which antibody to use. This retrospective review of our experience with Pmab in 13 EGFR antibody-naive patients and in 22 patients previously treated with Cmab for mCRC highlights a lack of hypersensitivity reactions (HSR) with Pmab, even in patients who experienced HSR to Cmab. In patients who received Cmab, 22% developed grade 3–4 HSR. There were no HSR on subsequent treatment with Pmab. We demonstrate similar activity in 95% of cases, between Cmab and Pmab both alone and in combination with chemotherapy in the treatment of mCRC. In one case we report unique sensitivity to Pmab after progression with Cmab.
Literature
1.
Bokemeyer C, Bondarenko I, Makhson A et al (2008) Fluorouracil, Leucovorin, and Oxaliplatin with and without Cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 29:29
2.
Rougier P, Stroiakovski D, Köhne C et al (2009) Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): Updated survival data and influence of KRAS status on outcome in the CRYSTAL study. American Society of Clinical Oncology-Gastrointestinal Cancer Symposium, Abstract # 443
3.
4.
5.
Folprecht G, Lutz MP, Schoffski P et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456. doi:10.​1093/​annonc/​mdj084 CrossRefPubMed
6.
7.
Tabernero J, Van Cutsem E, Diaz-Rubio E et al (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225–5232. doi:10.​1200/​JCO.​2007.​13.​2183 CrossRefPubMed
8.
Cervantes A, Casado E, Van Cutsem E (2005) Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study. Eur J Cancer Suppl 3:181–182
9.
10.
Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319. doi:10.​1200/​JCO.​2007.​13.​1193 CrossRefPubMed
11.
Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664. doi:10.​1200/​JCO.​2006.​08.​1620 CrossRefPubMed
12.
13.
Mano M, Humblet Y (2008) Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat Clin Pract Oncol 5:415–425. doi:10.​1038/​ncponc1136 CrossRefPubMed
14.
Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810. doi:10.​1200/​JCO.​2005.​08.​037 CrossRefPubMed
15.
16.
Bokemeyer C, Bondarenko I, Hartmann JT et al (2008) KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 26:4000CrossRef
17.
18.
19.
20.
Van Cutsem E, Lang I, D'haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26:2CrossRef
21.
22.
De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508–515. doi:10.​1093/​annonc/​mdm496 CrossRefPubMed
23.
Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237. doi:10.​1200/​JCO.​2006.​10.​5437 CrossRefPubMed
24.
Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 10:10
25.
26.
Langerak A, River G, Mitchell E et al (2009) Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin Colorectal Cancer 8:49–54. doi:10.​3816/​CCC.​2009.​n.​008 CrossRefPubMed
27.
Saif MW, Peccerillo J, Potter V (2008) Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 10:10
28.
29.
Hecht JR, Mitchell E, Chidiac T et al (2008) A randomized phase IIIB Trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 29:29
30.
31.
Pfeiffer P, Nielsen D, Yilmaz M et al (2007) Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 46:697–701. doi:10.​1080/​0284186060100945​5 CrossRefPubMed
32.
33.
Peeters M, Wilson G, Ducreux M et al (2008) Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. J Clin Oncol 26:4064
34.
Douillard J, Siena S, Cassidy J et al (2008) Phase III study (PRIME/20050203) of panitumumab with FOLFOX4 compared to FOLFOX4 alone in patients with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety data. American Society of Clinical Oncology-Gastrointestinal Cancer Symposium, Abstract # 443
35.
Freeman D, Sun J, Bass R et al (2008) Panitumumab and cetuximab epitope mapping and in vitro activity. J Clin Oncol 26:14536
36.
37.
38.
Pfeiffer P, Nielsen D, Bjerregaard J et al (2008) Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 19:1141–1145. doi:10.​1093/​annonc/​mdn020 CrossRefPubMed
39.
40.
Peeters M, Van Cutsem E, Berlin J et al (2007) Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. J Clin Oncol 25:4138
41.
42.
43.
Saif MW, Peccerillo J, Potter V (2009) Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 63:1017–1022. doi:10.​1007/​s00280-008-0831-6 CrossRefPubMed
44.
45.
NCT00418938 (2009) SPIRITT-Q2W FOLFIRI Regimen Plus Panitumumab or a Q2W FOLFIRI Regimen Plus Bevacizumab for 2nd-Line mCRC. www.​clinicaltrials.​com – last updated 05/07/2009
46.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648. doi:10.​1158/​0008-5472.​CAN-06-4158 CrossRefPubMed
Metadata
Title
Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience
Authors
Derek G. Power
Manish A. Shah
Timothy R . Asmis
Joaquin J . Garcia
Nancy E. Kemeny
Publication date
01-06-2010
Publisher
Springer US
Published in
Investigational New Drugs / Issue 3/2010
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-009-9268-y

Other articles of this Issue 3/2010

Investigational New Drugs 3/2010 Go to the issue

PRECLINICAL STUDIES

Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent

PRECLINICAL STUDIES

Ongoing DNA synthesis in the rat cerebral cortex is regulated by a proteolytic pathway independent of the proteasome and calpains

PRECLINICAL STUDIES

The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy

PHASE II STUDIES

Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer

PRECLINICAL STUDIES

Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants

PRECLINICAL STUDIES

MMPT: a thiazolidin compound inhibits the growth of lung cancer H1792 cells via Fas-mediated and caspase-dependent apoptosis pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits